Introduction GTC Biotherapeutics, rebranded as rEVO Biologics in 2013, is a biotech company based in Massachusetts, that specializes in creating therapeutic proteins using transgenic animals. They are credited with creating ATryn, the first-ever protein created by a transgenic animal and approved by regulatory bodies. Besides ATryn, the company is invested in the development of recombinant proteins and monoclonal antibodies for use in treating hematology, oncology, and autoimmune diseases. |
Target |
Mechanism thrombin inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseWithdrawn |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date28 Jul 2006 |
Target |
Mechanism AFP modulators |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism F10 stimulants [+2] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2018 |
Sponsor / Collaborator Mayo Clinic [+1] |
Start Date11 Jul 2014 |
Sponsor / Collaborator |
Start Date01 Apr 2014 |
Sponsor / Collaborator rEVO Biologics, Inc. [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Antithrombin alfa ( thrombin ) | Antithrombin III Deficiency More | Withdrawn |
Recombinant alpha-fetoprotein(Merrimack Pharmaceuticals, Inc.) ( AFP ) | Rheumatoid Arthritis More | Discontinued |
Recombinant factor VIII(rEVO Biologics, Inc.) ( F10 ) | Hemophilia A More | Pending |